Pharmaceutical Medicine

, Volume 32, Issue 2, pp 123–129 | Cite as

Adverse Event Reporting Patterns of Marketing Authorization Holders, Healthcare Professionals and Patients in Japan: Lessons Learnt From the Human Papilloma Virus Vaccine

Short Communication
  • 23 Downloads

Abstract

Background

A patient organization was founded in 2013 due to skepticism about the safety of human papilloma virus (HPV) vaccines.

Objective

To evaluate the impact of “priming” patients with information on adverse events following immunization (AEFI) via mainstream media and its impact on reporting by marketing authorization holders (MAHs), healthcare professionals (HCPs), and patients, and to assess the contribution of a pilot patient reporting system for adverse events in Japan to pharmacovigilance.

Methods

A summary list of reports of anaphylaxis, vagal reflex, and generalized pain-related AEFI, as presented to the Vaccine Adverse Reactions Review Committee (VARRC) between 2011 and 2016, was analyzed to gain information on MAH and HCP reports. Data on patient AEFI reporting were obtained from a pilot Pharmaceuticals and Medical Devices Agency (PMDA) database designed for this purpose. Data on vaccine shipment volumes were obtained from the VARRC.

Results

The leading reporting source transitioned from MAHs (82% of the total AEFI reported in 2010) to HCPs (63% in 2011), and patients (43% in 2015). Sharp peaks were observed for both MAH and HCP reports in 2011. A second peak in pain-related AEFIs reported by HCPs was observed in 2013 when the Ministry of Health, Labour and Welfare suspended the active recommendation of HPV vaccines. Patient reports were continuous and accounted for 21.7% of the total AEFIs reported to the current patient reporting system.

Conclusion

In Japan, the characteristics of AEFI reports differed by source for HPV vaccines. MAH and HCP reports identified the major trend in AEFI occurrence during the early post-marketing phase, whereas patient reports in cooperation with HCPs facilitated the detection of weak signals of possible AEFIs throughout the product lifecycle. Patient reporting systems should be encouraged, especially by promoting the communication between patients and local “home” pharmacies in cooperation with patient organizations.

Notes

Acknowledgements

The authors thank Professor Robert Kneller and Mr. Cameron Wright for the intellectual guidance.

Compliance with Ethical Standards

Conflict of interest

Yasuko Inokuma, Yasuyuki Sato, and Sachiko Masuda declare that they have no conflict of interest.

Funding

No funding was received to support this manuscript.

References

  1. 1.
    Landmark approval paves the way for access to the vaccine for women in Japan. In: GSK’s Cervarix® becomes the first cervical cancer vaccine to gain approval in Japan. GlaxoSmithKline plc. 2009. http://www.gsk.com/en-gb/media/press-releases/2009/gsk-s-cervarix-becomes-the-first-cervical-cancer-vaccine-to-gain-approval-in-japan. Accessed March 2017.
  2. 2.
    MSD’s newly released Gardasil®, providing a new choice for the prevention of HPV. MSD KK. 2011. http://www.msd.co.jp/newsroom/msd-archive/2011/product_news_0826.xhtml. Accessed March 2017.
  3. 3.
    Outline of the amendment of Immunization Act. Ministry of Health, Labour and Welfare. 2013. http://www.mhlw.go.jp/topics/bcg/tp250330-2.html. Accessed March 2017.
  4. 4.
    National Network for victim of HPV vaccine. 2017. http://hpvv-danger.jp/. Accessed December 2017 (in Japanese).
  5. 5.
    Material 2-5. In: Joint meeting of the Vaccine Adverse Reactions Review Committee. Ministry of Health, Labour and Welfare. 2013. http://www.mhlw.go.jp/stf/shingi/2r98520000034g8f-att/2r98520000034hsc_1.pdf. Accessed March 2017.
  6. 6.
    Corresponding to the routine vaccination of HPV vaccine (recommendation). Health Service Bureau 0614-1, Director of Health Service Bureau, Ministry of Health, Labour and Welfare. 2013. http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou28/pdf/kankoku_h25_6_01.pdf. Accessed March 2017.
  7. 7.
    Gilmour S, Kanda M, Kusumi E, Tanimoto T, Kami M, Shibuya K. HPV vaccination programme in Japan. Lancet. 2013;382:768.CrossRefPubMedGoogle Scholar
  8. 8.
    Global advisory committee on vaccine safety statement on safety of HPV vaccines. World Health Organization. 2015. http://www.who.int/vaccine_safety/committee/GACVS_HPV_statement_17Dec2015.pdf. Accessed March 2017.
  9. 9.
    Safety of Hib vaccine, pneumococcal vaccine, and HPV vaccine. Ministry of Health, Labour and Welfare. 2013. http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou28/oldindex.html. Accessed March 2017 (in Japanese).
  10. 10.
    Information of suspected ADR sent from patients, Pharmaceuticals and Medical Devices Agency. 2017. https://www.pmda.go.jp/safety/reports/patients/0002.html. Accessed March 2017.
  11. 11.
    Duh MS, Cremieux P, Audenrode MV, Vekeman F, Karner P, Zhang H, Greenberg P. Can social media data lead to earlier detection of drug-related adverse events? Pharmacoepidemiol Drug Saf. 2016;25:1425–33.  https://doi.org/10.1002/pds.4090.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Trifirò G, Patadia V, Schuemie MJ, Coloma PM, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Giaquinto C, Scotti L, Pedersen L. EU-ADR healthcare database network vs. spontaneous reporting system database: preliminary comparison of signal detection. Stud Health Technol Inform. 2011;166:25–30.PubMedGoogle Scholar
  13. 13.
    Hammond IW, Rich DS, Gibbs TG. Effect of consumer reporting on signal detection: using disproportionality analysis. Expert Opin Drug Saf. 2007;6:705–12.CrossRefPubMedGoogle Scholar
  14. 14.
    Regulation (EU) No 1235/2010 of the European parliament and of the council of 15 December 2010. In: Official Journal of the European Union. 2010. http://ec.europa.eu/health/files/eudralex/vol-1/reg_2010_1235/reg_2010_1235_en.pdf. Accessed October 2017.
  15. 15.
    Inokuma Y. Pharmacovigilance of regenerative medicine under the amended pharmaceutical affairs act in Japan. Drug Saf. 2017;40:475–82.CrossRefPubMedGoogle Scholar
  16. 16.
    Reports of Adverse Drug Reactions from Patient. Pharmaceuticals and Medical Devices Agency. https://www.pmda.go.jp/safety/reports/patients/0004.html. Accessed July 2017.
  17. 17.
    Gäwert L, Hierse F, Zink A, Strangfeld A. How well do patient reports reflect adverse drug reactions reported by rheumatologists? Agreement of physician-and patient-reported adverse events in patients with rheumatoid arthritis observed in the German biologics register. Rheumatology. 2010;50:152–60.CrossRefPubMedGoogle Scholar
  18. 18.
    Hunsel F, Waal S, Härmark L. The contribution of direct patient reported ADRs to drug safety signals in the Netherlands from 2010 to 2015. Pharmacoepidemiol Drug Saf. 2017.  https://doi.org/10.1002/pds.4236.PubMedCentralGoogle Scholar
  19. 19.
    Summary of safety counter measures for pharmaceuticals taken in 2016. Ministry of Health, Labour and Welfare. 2017. http://www.mhlw.go.jp/file/05-Shingikai-11121000-Iyakushokuhinkyoku-Soumuka/0000171427.pdf. Accessed August 2017.
  20. 20.
    Inokuma Y. Patient report system in Japan, Lareb Conference on Patient Reporting, April 23–24. 2015.Google Scholar
  21. 21.
    Vision of home pharmacy for patients. Ministry of Health, Labour and Welfare. 2015. http://www.mhlw.go.jp/file/04-Houdouhappyou-11121000-Iyakushokuhinkyoku-Soumuka/vision_1.pdf. Accessed September 2017.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Research Center for Advanced Science and TechnologyThe University of TokyoTokyoJapan
  2. 2.Clinical Research Center, Graduate School of MedicineChiba UniversityChibaJapan

Personalised recommendations